LMenghaney

1.7K posts

LMenghaney

LMenghaney

@LMenghaney

Feminist working on access to treatment issues. Follow issues related to generic production and patents closely. Views are my own.

Katılım Ocak 2013
600 Takip Edilen1.5K Takipçiler
Sabitlenmiş Tweet
LMenghaney
LMenghaney@LMenghaney·
In area of IP, PublicHealth & access to medicines, Modi govt sh consider its independence 2 be of utmost importance tinyurl.com/hwsdrdr
English
0
16
25
0
LMenghaney
LMenghaney@LMenghaney·
To reporters who ask: US President’s tweet on 100% import tariffs on pharma products targets branded drugs, leaving affordable generics out. An unbranded generic? A Phoenix—unseen in health systems.
English
1
0
0
55
LMenghaney
LMenghaney@LMenghaney·
The US imposes 100% tariffs on generic medicines from India. Result? Millions of US patients face skyrocketing costs 💊💉Share prices may bounce back, but patients bear the real cost of treatment interruptions. #AccessToMedicines
English
0
0
3
51
LMenghaney retweetledi
businessline
businessline@businessline·
Patients with Spinal Muscular Atrophy are hopeful of getting access to generic versions of Roche’s patented drug Risdiplam, following Delhi High Court’s denial of an interim injunction request from the Swiss drugmaker. Click here to read more: @jo_da123 trib.al/zBEx2ks
English
0
4
4
511
LMenghaney retweetledi
jyothidatta
jyothidatta@jo_da123·
In the noise over tariffs, intellectual property (IP) has not yet been stated out loud as a negotiating tool, but it waits in the wings, say economists. This, even as the clock ticks on the USTR's Special 301 report.#pharma IP in the time of tariff wars  thehindubusinessline.com/specials/pulse…
English
0
4
2
226
LMenghaney
LMenghaney@LMenghaney·
@mellabarb Aimed at blocking the buyers clubs that PLHIV networks run to support PLHIVs who do not have access to the generic in their jurisdiction.
English
0
0
0
24
LMenghaney retweetledi
MSF Access
MSF Access@MSF_access·
Today on #WorldDiabetesDay, we’re at @NovoNordisk offices in Johannesburg w/ a message: 📢Resume the supply of insulin pens in South Africa AND 📢DROP THE PRICE to $1/pen so ALL people living w/ #diabetes can manage their treatment. Insulin pens shouldn’t be a luxury!
English
1
25
43
3.7K
LMenghaney
LMenghaney@LMenghaney·
On our way to the @novonordisk office in Joburg to demand that they stop the #DoubleStandard in Diabetes Tx. Our demand stop the profiterring and supply the insulin pen @$1 to South Africa!
Johannesburg, South Africa 🇿🇦 English
0
0
0
73
LMenghaney
LMenghaney@LMenghaney·
@mellabarb @mellabarb, you are right. Licensees supplying to a country that issues a CL or does not have a granted patent could violate the anti-diversion clauses. @GileadSciences should issue a clarification that it will not block supply under CL or where there are no granted patents.
English
0
0
0
21
LMenghaney retweetledi
More Perfect Union
More Perfect Union@MorePerfectUS·
NEW: One miracle drug could create a fiscal crisis in America. Ozempic could end obesity...bankrupt Medicare, blow up state budgets and increase premiums for everyone. It’s because Big Pharma is ripping us off. The drug costs $936 in the US—but nearly 10x less everywhere else.
English
21
210
672
46K
LMenghaney
LMenghaney@LMenghaney·
South Africa's Competition Commission continues to deliver access by investigating anti-competitive "evergreening" practices in the patent system, but we need patent laws & patent examiners to prevent ever-greening wh extend monopolies on known meds! @MSF_access @HealthJusticeIn
Spotlight@SpotlightNSP

We scored a big win when J&J dropped their patent on #TB medicine after the @CompComSA initiated a probe. 20 years ago, a similar case helped drive down #antiretroviral prices, write @_HassanF and Leena Menghaney. @HealthJusticeIn @MSF @HealthJusticeIn spotlightnsp.co.za/2024/08/30/com…

English
0
5
12
1.2K
LMenghaney
LMenghaney@LMenghaney·
This is a momentous day for people with DR-TB. India will finally replace many of the longer, less-effective tx by offering safer and shorter BPaLM regimen that is more effective in curing this deadly disease.
LMenghaney@LMenghaney

MSF welcomes NTEP's step to introduce BPaL & BPaL/M - a significant breakthrough in the battle against MDR in India. The next step is to also introduce delamanid based short oral regimens for children and as an alternative for people who cannot tolerate bedaquiline or linezolid.

English
0
4
12
1.1K
LMenghaney
LMenghaney@LMenghaney·
MSF welcomes NTEP's step to introduce BPaL & BPaL/M - a significant breakthrough in the battle against MDR in India. The next step is to also introduce delamanid based short oral regimens for children and as an alternative for people who cannot tolerate bedaquiline or linezolid.
Soumya Swaminathan@doctorsoumya

India is getting ready to roll out BPaL regimen for all M/XDRTB patients - training to begin this month. This should improve treatment outcomes & help thousands of patients. Scaling up NAAT coverage will be an essential element of the strategy @WHO @StopTB @TBHDJ @MoHFW_INDIA

English
0
2
10
2.1K